ArticleMolecular therapy. Methods & clinical development2025

Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engager.

Mark A Currier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.